# psoriasis - claude-opus-4-8

- Benchmark system: raw
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 7746
- Completion tokens: 5583
- Reasoning tokens: 
- Total tokens: 13329
- API requests reported: 
- Elapsed seconds: 91.176
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: Anthropic

---
## Overall Biological Interpretation

The transcriptomic signature of psoriatic lesional skin reflects a coordinated inflammatory-hyperproliferative state driven primarily by the IL-36/IL-17/IL-23 cytokine axis. The dataset reveals three tightly integrated biological layers: (1) keratinocyte hyperactivation with simultaneous proliferation and aberrant differentiation, evidenced by SPRR, LCE, and stress keratin expression; (2) profound upregulation of innate immune effectors including IL-36 family cytokines, antimicrobial peptides (defensins, S100 alarmins), and neutrophil chemoattractants; and (3) metabolic reprogramming affecting lipid handling and inflammatory mediator synthesis. Notably, the transcriptional response is heavily skewed toward upregulation (>95 upregulated genes vs. ~10 downregulated), consistent with an active inflammatory-proliferative program rather than loss of homeostatic functions. The downregulated genes are sparse and less well-characterized, suggesting the dominant pathology is gain-of-function rather than loss of barrier or regulatory mechanisms.

---

## Core Biological Programs

### 1. IL-36-Mediated Inflammatory Amplification Loop

**Direction:** Strongly upregulated  
**Major supporting genes:** IL36A (log2FC 11.37), IL36G (log2FC 5.68), IL19 (log2FC 7.58), IL20 (log2FC 5.67), IL26 (log2FC 4.36), IL36RN (log2FC 3.01)  
**Pathway:** GO:0070498 (interleukin-36-mediated signaling pathway); Reactome R-HSA-9020702 (Interleukin-36 pathway)  

**Interpretation:** The IL-36 family (IL36A, IL36G, and the receptor antagonist IL36RN) is among the most dramatically upregulated gene set, with IL36A showing the third-highest fold change in the entire dataset. IL-36 cytokines are epithelial-derived pro-inflammatory mediators that act on both keratinocytes and immune cells, creating positive feedback amplification. The co-expression of IL19, IL20, and IL26 (all IL-20 subfamily members) indicates broad activation of IL-10 family inflammatory cytokines that signal through shared receptor complexes and synergize with IL-17 signaling. These cytokines collectively drive keratinocyte activation, immune cell recruitment, and antimicrobial responses. The simultaneous induction of IL36RN (the natural antagonist) represents an insufficient negative feedback attempt.

**Evidence strength and limitations:** Very strong dataset support (multiple independent genes, high fold changes, very low FDR). Extensive disease-association evidence from GWAS (IL36RN loss-of-function mutations cause pustular psoriasis) and clinical trials (anti-IL-36R antibodies effective in pustular psoriasis). Primary limitation: this dataset cannot distinguish whether IL-36 upregulation is a primary driver or downstream consequence of IL-17/IL-23 activation. IL-36 and IL-17 pathways are mutually reinforcing, making causal directionality ambiguous from cross-sectional expression data alone.

---

### 2. Antimicrobial Peptide and Alarmin Response

**Direction:** Strongly upregulated  
**Major supporting genes:** S100A7A (log2FC 9.83), S100A7 (log2FC 7.09), S100A8 (log2FC 7.73), S100A12 (log2FC 8.33), DEFB4A (log2FC 11.18), DEFB4B (log2FC 11.03), DEFB103A (log2FC 5.76), DEFB103B (log2FC 5.75), PI3/elafin (log2FC 9.24)  
**Pathway:** GO:0019730 (antimicrobial humoral response); GO:0002227 (innate immune response in mucosa); Reactome R-HSA-6798695 (Neutrophil degranulation)  

**Interpretation:** Psoriatic lesions exhibit massive upregulation of antimicrobial peptides spanning multiple structural families: S100 alarmins (calcium-binding proteins with both antimicrobial and pro-inflammatory DAMP activity), β-defensins (DEFB4A/B, DEFB103A/B), and serine protease inhibitors with antimicrobial function (PI3/elafin). S100A7 (psoriasin) and S100A7A are among the most psoriasis-specific markers. The S100A8/A12 proteins are typically neutrophil-derived, though keratinocytes also produce them under inflammatory conditions. This dual antimicrobial-inflammatory function positions these molecules as both protective innate immune effectors and inflammatory amplifiers. Their expression is directly induced by IL-17, IL-36, and TNF signaling.

**Evidence strength and limitations:** Very strong dataset support and disease-association evidence (S100A7 highly specific to psoriasis vs. other inflammatory dermatoses). Direct regulatory evidence links IL-17/IL-36 to AMP induction. Major limitation: cellular source ambiguity. S100A8, S100A12, and DEFB proteins can derive from infiltrating neutrophils, resident keratinocytes, or both. Bulk RNA-seq cannot deconvolve this; single-cell analysis or immunohistochemistry would be required. While these AMPs are undoubtedly elevated in psoriatic tissue, attributing specific cellular sources and distinguishing cause from effect requires additional validation.

---

### 3. Keratinocyte Hyperproliferation and Altered Terminal Differentiation

**Direction:** Upregulated  
**Major supporting genes:** SPRR2A (log2FC 7.31), SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3, LCE3A (log2FC 8.30), LCE3D (log2FC 5.31), KRT6A (log2FC 4.30), RRM2 (log2FC 2.72), CCNE1 (log2FC 2.56)  
**Pathway:** GO:0031424 (keratinization); GO:0070268 (cornification); Hallmark_E2F_TARGETS  

**Interpretation:** The coordinated upregulation of small proline-rich proteins (SPRR2 family, SPRR3) and late cornified envelope proteins (LCE3A, LCE3D) reflects simultaneous hyperproliferation and altered terminal differentiation. In healthy epidermis, SPRR and LCE proteins are expressed in suprabasal differentiating keratinocytes and cross-linked into the cornified envelope. In psoriasis, these genes are massively overexpressed, and the differentiation program is dysregulated—cells proliferate rapidly (supported by RRM2 and CCNE1, which regulate DNA synthesis and G1/S transition) while also expressing terminal differentiation markers, resulting in the characteristic thick, scaling plaques. KRT6A is a stress-induced keratin pair (with KRT16) that replaces KRT1/KRT10 during hyperproliferation and wound healing. The SPRR2 gene cluster on chromosome 1q21.3 is within the epidermal differentiation complex, a region with strong genetic association with psoriasis.

**Evidence strength and limitations:** Strong dataset support (multiple independent genes from coordinated genomic clusters) and disease-association evidence (genetic studies, histologic correlation). Known regulatory evidence: STAT3, induced by IL-17/IL-22, directly transactivates SPRR and LCE genes. Limitation: this represents a descriptive hallmark of psoriasis rather than a primary driver. The hyperproliferative-differentiation phenotype is downstream of immune signals (primarily IL-17, IL-22, IL-36), not autonomous keratinocyte dysregulation. Distinguishing primary epidermal defects from secondary immune-driven changes requires loss-of-function genetic models or temporal analysis.

---

### 4. Neutrophil Recruitment and Myeloid Cell Activation

**Direction:** Upregulated  
**Major supporting genes:** CXCR2 (log2FC 2.70), CXCL13 (log2FC 5.89), HPSE (log2FC 2.92), TNIP3 (log2FC 7.28), IRAK2 (log2FC 2.08)  
**Pathway:** GO:0030593 (neutrophil chemotaxis); GO:0002283 (neutrophil activation involved in immune response); Reactome R-HSA-6798695 (Neutrophil degranulation)  

**Interpretation:** Neutrophil recruitment is a defining histologic feature of psoriasis (Munro microabscesses in the stratum corneum, spongiform pustules of Kogoj in the epidermis). CXCR2, the receptor for CXCL1/CXCL2/CXCL8 (IL-8), is upregulated, likely reflecting infiltrating neutrophils or activated keratinocytes that induce neutrophil-attracting chemokines. HPSE (heparanase) degrades heparan sulfate in the extracellular matrix, facilitating immune cell migration and releasing sequestered growth factors and chemokines. TNIP3 (TNFAIP3-interacting protein 3) is induced by inflammatory signals and modulates NF-κB signaling. IRAK2 (IL-1 receptor-associated kinase 2) is a key signal transducer downstream of IL-1/IL-36 receptors and TLRs, directly linking this module to the IL-36 program. CXCL13, typically a B-cell chemoattractant, is unexpectedly elevated and may reflect ectopic lymphoid neogenesis or broader lymphocyte recruitment.

**Evidence strength and limitations:** Moderate dataset support (fewer independent genes; CXCR2 fold change modest). Strong histologic and clinical evidence (neutrophilic infiltration is a cardinal feature). Cellular composition confound: CXCR2 and myeloid signaling genes may primarily reflect infiltrating neutrophils rather than tissue-resident keratinocyte responses, making it unclear whether their upregulation represents active transcription in tissue cells or simply increased neutrophil cellularity. This is testable via single-cell RNA-seq or immunohistochemistry co-localization. CXCL13 elevation is more exploratory; while B cells and tertiary lymphoid structures are present in chronic psoriatic lesions, CXCL13's functional role in plaque psoriasis is less established than in psoriatic arthritis.

---

### 5. Lipid Metabolism and Oxidative Stress Response Reprogramming

**Direction:** Mixed (primarily upregulated with selective downregulation)  
**Major supporting genes:** AKR1B10 (log2FC 6.27), AKR1B15 (log2FC 5.23), FABP5 (log2FC 3.64), PLA2G4D (log2FC 4.61), PLA2G4E (log2FC 2.47); downregulated: BTC (log2FC -4.30), CYP2W1 (log2FC -4.70), UGT3A2 (log2FC -4.59)  
**Pathway:** GO:0006629 (lipid metabolic process); GO:0055114 (oxidation-reduction process); KEGG Arachidonic acid metabolism  

**Interpretation:** AKR1B10 and AKR1B15 (aldo-keto reductase family 1B) catalyze the reduction of retinaldehyde to retinol and metabolize lipid aldehydes, playing roles in retinoic acid homeostasis, fatty acid synthesis, and detoxification of lipid peroxidation products. Their dramatic upregulation suggests metabolic reprogramming in psoriatic keratinocytes, potentially supporting rapid proliferation or responding to oxidative stress.
